Ignite Creation Date:
2024-05-06 @ 3:44 AM
Last Modification Date:
2024-10-26 @ 11:38 AM
Study NCT ID:
NCT02366026
Status:
UNKNOWN
Last Update Posted:
2016-02-23
First Post:
2015-02-06
Brief Title:
REMUNE AMPLIVAX IR103 HIVAIDS Phase III Safety Efficacy Study
Sponsor:
Immune Response BioPharma Inc
Organization:
Immune Response BioPharma Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-06
Start Date Type:
None
Primary Completion Date:
2019-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2019-06
Completion Date Type:
ESTIMATED
First Submit Date:
2015-02-06
First Submit QC Date:
February 11 2015
Study First Post Date:
2015-02-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-02-22
Last Update Post Date:
2016-02-23
Last Update Post Date Type:
ESTIMATED